The requirement for the favorable therapeutics against ulcerative colitis (UC) is that anti-
inflammatory drugs can be specifically internalized by macrophages and subsequently be …

Orally targeted delivery of anti-inflammatory drugs to macrophages has attracted great
attention for minimizing the symptoms of ulcerative colitis (UC). In this investigation, we …

Oral nanoparticles have been considered a prospective drug delivery carrier against
ulcerative colitis (UC). To enhance the mucus-penetrating capacity and aqueous solubility …

In this study, we developed oral core–shell nanoparticles composed of curcumin
nanocrystals in the core and chitosan/alginate multilayers in the shell for inflammation …

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease that features
colonic epithelial barrier dysfunction and gut dysbiosis. Preclinical studies demonstrated that …

Ulcerative colitis (UC) with its rapidly increasing incidence has become an emerging
challenge for public health. Therapeutic agents are required to be specifically delivered to …

Combination therapy is an emerging strategy that is under intensive preclinical investigation
for the treatment of various diseases. CD98 is highly overexpressed on the surfaces of …

Although nano-systems can promote the cellular internalization, polymeric nanoparticles
(NPs) are easily to be destroyed or eliminated in the gastrointestinal tract, which leads to …

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) of unknown etiology
affecting the colon and rectum. Previous studies have found that reactive oxygen species …

Ulcerative colitis (UC) is one type of inflammatory bowel disease (IBD) and lactoferrin (LF) is
a promising protein drug to treat UC. However, targeted LF delivery to optimize …